Indications & Uses
Pertuza 420 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage For intravenous infusion only; it should not be given as an intravenous push or bolus. The initial Pertuzumab dose is 840 mg, given as a 60 minute intravenous infusion, followed every 3 weeks thereafter by 420 mg given as a 30 to 60 minute intravenous infusion. Metastatic breast cancer: Pertuzumab should be given together with Trastuzumab and Docetaxel by intravenous infusion every 3 weeks. Neoadjuvant use: Pertuzumab should be given together with Trastuzumab and Docetaxel by intravenous infusion before surgery, every 3 weeks, for 3 to 6 cycles. Pediatric use: The safety and effectiveness of Pertuzumab have not been established in pediatric patients.
Side Effects
Left Ventricular Dysfunction: Perjeta can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF. Evaluate cardiac function prior to and during treatment. Discontinue Perjeta treatment for a confirmed clinically significant decrease in left ventricular function.Embryo-fetal Toxicity: Exposure to Perjeta can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Patients should be advised of these risks and the need for effective contraception.Metastatic Breast Cancer: The most common adverse reactions (> 30%) with Perjeta in combination with Trastuzumab and Docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.Neoadjuvant Treatment of Breast Cancer: The most common adverse reactions (>30%) with Perjeta in combination with Trastuzumab and Docetaxel were alopecia, diarrhea, nausea, and neutropenia. The most common adverse reactions (>30%) with Perjeta in combination with Trastuzumab and Docetaxel when given for 3 cycles following 3 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia. The most common adverse reactions (>30%) with Perjeta in combination with Docetaxel, Carboplatin, and Trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.
Cautions & Contraindications
Warnings & Precautions
Left Ventricular Dysfunction: Heart pumping function (LVEF) should be monitored, and doses should be withheld as needed. Embryo-Fetal Toxicity: This medicine can harm the developing embryo or fetus if given to a pregnant woman. Infusion-Related Reactions: Patients should be watched for signs and symptoms during infusion. If a significant infusion-related reaction occurs, the infusion should be slowed or stopped and suitable medical treatment given. Hypersensitivity Reactions/Anaphylaxis: Patients should be watched for signs and symptoms. If a severe hypersensitivity reaction or anaphylaxis occurs, the infusion should be stopped immediately and suitable medical treatment given.
Contraindications
Pertuzumab should not be used in anyone with a known hypersensitivity to pertuzumab itself or to any of the excipients in the formulation.